IDEAYA registers Phase 3 adjuvant trial of darovasertib plus crizotinib in uveal melanomaSep 4Trial updatecrizotinibdarovasertib
IDEAYA reports Q2 2026 results, darovasertib trial hits primary endpointAug 4Quarterly updatedarovasertibIDEAYA Biosciences
Sign inSign in